A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic arthritis subtypes of psoriatic and enthesitis-related arthritis - Secukinumab safety and efficacy in JPsA and ERA A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safe ...
Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: PT;Classification code 10076674;Term: Juvenile psoriatic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0;Level: LLT;Classification code 10072745;Term: Enthesitis related arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis MedDRA version: 20.0;Level: PT;Classif ...
Trade Name: COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 1 SIRINGA PRERIEMPITA Product Name: NA Product Code: AIN457F INN or Proposed INN: SECUKINUMAB Other descriptive name: SECUKINUMAB Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: SECUKINUMABTrade Name: COSENTYX- 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRI ...
NOVARTIS PHARMA AG
NULL
Not Recruiting
Female: yes Male: yes
80
Phase 3
United States;Spain;Poland;Belgium;Turkey;Netherlands;Germany;United Kingdom;Italy